Tag: Gene editing IP landscape analysis
Comprehensive Analysis: Gene Editing IP, Lysosomal Therapy Access, Newborn Screening AI, and Zolgensma Cost – Effectiveness
Stay ahead in the rapidly evolving biotech landscape with this comprehensive buying guide! This 2024 analysis delves into crucial areas like gene editing IP, lysosomal therapy access, newborn screening AI, and Zolgensma cost – effectiveness. According to a SEMrush 2023 Study and the University of Pennsylvania (2022), the gene editing IP has over 2,072 patent